USFDA observations at Bachupally facility
USFDA issued a post-action letter for observations at the Bachupally biologics facility, potentially delaying rituximab and denosumab approvals.
DRREDDY / Q3-FY26 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Lenalidomide revenue cliff from Q4
Management advised assuming zero lenalidomide revenue from Q4 FY26, which will impact overall revenue and margins.
Semaglutide pricing pressure in Canada
Management acknowledged that semaglutide pricing may be at the lower end of the $20-70 range due to competition, including Novo Nordisk's own generic.
Biosimilar denosumab delay in US
CRL for denosumab from Alvotech facility may push US approval to Q2 FY27 or later, impacting biosimilar revenue expectations.